Short Interest in Fortress Biotech, Inc. (NASDAQ:FBIOP) Expands By 1,042.9%

Fortress Biotech, Inc. (NASDAQ:FBIOP) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 8,000 shares, an increase of 1,042.9% from the July 15th total of 700 shares. Based on an average trading volume of 20,200 shares, the days-to-cover ratio is presently 0.4 days.

Fortress Biotech Stock Performance

Shares of NASDAQ FBIOP traded down $0.31 during midday trading on Monday, hitting $6.80. The stock had a trading volume of 50,377 shares, compared to its average volume of 16,061. Fortress Biotech has a 1 year low of $6.40 and a 1 year high of $18.00. The stock has a 50 day simple moving average of $12.11 and a 200-day simple moving average of $14.32.

Fortress Biotech Dividend Announcement

The business also recently declared a monthly dividend, which was paid on Sunday, June 30th. Investors of record on Saturday, June 15th were issued a $0.1953 dividend. The ex-dividend date was Friday, June 14th. This represents a $2.34 annualized dividend and a dividend yield of 34.47%.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.